cdmo.directory
← Compare landing

Esco Aster vs uBriGene

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/escoaster/ubrigene

CategoryEsco AsteruBriGene
Listed sitebothboth
SummaryEsco Aster is a vertically integrated CDMO and CRO delivering end-to-end contract solutions from process development and GMP manufacturing through clinical research, with specialized capabilities in vaccine production, cell therapy, plasmid DNA, extracellular vesicles, and GLP toxicology.uBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing. Headquartered in Maryland with operations across North America and Asia, the company specializes in bridging ATMP concepts from early…
Services
  • Translational Research
  • Clinical Trial Services
  • GLP Toxicology
  • Preclinical In Vitro Studies
  • Preclinical In Vivo Studies
  • Analytical Method Development & Validation
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Translational Research
Modalities
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
Indications
  • Neurology
  • Infectious Disease
  • Respiratory
  • Dermatology
  • Oncology
LocationsData not yet provided.
  • Headquarters, Maryland, Maryland, USA
  • Boston, Boston, Massachusetts, USA
  • Worcester, Worcester, Massachusetts, USA
Certifications
  • cGMP · Identifier: cGMP-compliant
  • GLP · Identifier: GLP Toxicology
  • FDA · Identifier: 20+ INDs filed and accepted
  • EMA · Identifier: 20+ INDs filed and accepted
  • NMPA · Identifier: 20+ INDs filed and accepted
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.